Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 16/20 | 0.71 |
| ▸ | PDE1B | Q01064 | 16/20 | 0.71 |
| ▸ | PDE1C | Q14123 | 16/20 | 0.71 |
| ▸ | ESR1 | P03372 | 2/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.62 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667091 | 1.00 | PDE1A (0.71) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL667090 | 1.00 | PDE1A (0.71) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL5071827 | 0.84 | POLB (0.52) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL3774574 | 0.83 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL19217 | 0.83 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL19216 | 0.83 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL20163507 | 0.81 | POLB (0.56) | — | |
| SCHEMBL8767423 | 0.81 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767419 | 0.81 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767418 | 0.81 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| CN-108348605-B | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20210186932-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20210140945-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | MADRIGAL PHARMACEUTICALS INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6352970-B1 | Treatment of skeletal disorders | PFIZER INC. | 2002-03-05 | — | — | US | disclosed |
| US-20020019351-A1 | Treatment of skeletal disorders | KE HUAZHU (US) | 2002-02-14 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0976404-A2 | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0950417-A2 | Treatment of skeletal disorders | Pfizer Products Inc. (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | PDE1A 3575/4885PDE1B 3477/4885PDE1C 3705/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | PDE1A 3536/4885PDE1B 3435/4885PDE1C 3680/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | PDE1A 3575/4885PDE1B 3477/4885PDE1C 3705/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PDE1A 785/4885PDE1B 799/4885PDE1C 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.